Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer

• DOI: 10.1126/scitranslmed.aaz3577
• Publication Date: 2020-04-01T23:15:29Z
• Authors: Sumit K. Subudhi; Luis Vence; Hao Zhao; Jorge Blando; Shalini S. Yadav; Qing Xiong; Alexandre Reuben; Ana Aparicio; Paul G. Corn; Brian F. Chapin; Louis L. Pisters; Patricia Troncoso; Rebecca Slack Tid...; Peter Thall; Chang-Jiun Wu; Jianhua Zhang; Christopher L. Lo...; Andrew Futreal; James P. Allison; Padmanee Sharma
• Keywords: Cohort Studies; Male; 0303 health sciences; 03 medical and health sciences; Antineoplastic Agents, Immunological; Biomarkers, Tumor; Humans; Prostatic Neoplasms; CD8-Positive T-Lymphocytes; Ipilimumab; 3. Good health

Low–tumor mutational burden prostate tumors express neoantigens that elicit T cell responses associated with favorable clinical outcomes to ipilimumab.